keyword
MENU ▼
Read by QxMD icon Read
search

Global oncology

keyword
https://www.readbyqxmd.com/read/29774809/robotic-partial-nephrectomy-for-a-peripheral-renal-tumor
#1
Caleb A Cooper, Cheuk Fan Shum, Chandru P Sundaram
Partial nephrectomy (PN) is the preferred surgical treatment for T1 renal tumors whenever technically feasible. When properly performed, it allows preservation of nephron mass without compromising oncologic outcomes. This reduces the postoperative risk of renal insufficiency, which translates into better overall survival for the patients. PN can be technically challenging, because it requires the surgeon to complete the tasks of tumor excision, hemostasis and renorrhaphy, all within an ischemic time of preferably below 30 minutes...
May 2018: Journal of Endourology
https://www.readbyqxmd.com/read/29774521/patient-reported-outcomes-of-multiple-myeloma-patients-treated-with-panobinostat-after-%C3%A2-2-lines-of-therapy-based-on-the-international-phase-3-randomized-double-blind-placebo-controlled-panorama-1-trial
#2
Paul G Richardson, Robert L Schlossman, Anuja N Roy, Ashok Panneerselvam, Suddhasatta Acharyya, Monika Sopala, Sagar Lonial
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48...
May 17, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29773225/-cognitive-decline-in-geriatric-oncology-trends-evaluation-and-treatment
#3
REVIEW
V Antoine, M Courtial, B de Wazieres, A Di Castri, S Duvjnak, L Geronimi, C Labarias, C Le Guillou, A Martin-Allier, D Matelot, C Moitrelle, F Santoni, G Solinas, M Viala
Cancer prevalence increases with aging. Prevalent or incident neurocognitive disorders are frequent in geriatric oncology. Cognitive decline associated with cancer increases the risk of under or over-cancer treatment and makes therapeutic decisions complex. In this context, we present tools to optimize cognitive impairment screening, identification of underlying mechanisms and specific treatments. Geriatric specialists intervention can help global care, social services utilization and patient's orientation when ambulatory cares become difficult...
May 14, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29755999/prescribing-pattern-and-prescription-writing-quality-of-antineoplastic-agents-in-the-capital-city-of-a-middle-income-developing-country
#4
Maryam Taghizadeh-Ghehi, Asiyeh Amouei, Ava Mansouri, Aarefeh Jafarzadeh Kohneloo, Molouk Hadjibabaie
Objective: Cancer is a global health concern with growing incidence worldwide. Chemotherapy is the main treatment modality in many malignancies. This study aimed at evaluation of antineoplastic prescribing pattern and prescription-writing quality in the capital city of Iran. Methods: All dispensed chemotherapy prescriptions by four main authorized pharmacies in Tehran during 1 month were targeted. Prescriptions with no antineoplastic medications or written by specialties other than oncology-related fields were excluded from the study...
January 2018: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29754192/gastrointestinal-disorders-associated-with-primary-immunodeficiency-diseases
#5
REVIEW
Stella Hartono, Michelina Rosa Ippoliti, Maria Mastroianni, Ricardo Torres, Nicholas L Rider
There are now 354 inborn errors of immunity (primary immunodeficiency diseases (PIDDs)) with 344 distinct molecular etiologies reported according to the International Union of Immunological Sciences (IUIS) (Clin Gastroenterol Hepatol 11: p. 1050-63, 2013, Semin Gastrointest Dis 8: p. 22-32, 1997, J Clin Immunol 38: p. 96-128, 2018). Using the IUIS document as a reference and cross-checking PubMed ( www.ncbi.nlm.nih.pubmed.gov ), we found that approximately one third of the 354 diseases of impaired immunity have a gastrointestinal component [J Clin Immunol 38: p...
May 13, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29753391/-attractiveness-of-france-for-international-clinical-research-8th-survey-conducted-by-leem-french-association-for-pharmaceutical-companies
#6
Ariane Galaup, Philippe Barthélémy, Brigitte Pouletty-Lefebvre, Jehan-Michel Béhier, Jean Zetlaoui, Thomas Borel
The Leem (French association of pharmaceutical companies) has conducted the eighth survey on attractiveness of France for clinical research. It serves to measure France's global competitiveness for international clinical trials and assess its strengths and areas of excellence. It also highlights the potential for progress and emerging trends at a time when the regulatory environment in France and Europe is undergoing change. This survey has been updated every two years since 2002 using the same methodology...
April 18, 2018: Thérapie
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#7
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29750673/quality-of-life-perception-cognitive-function-and-psychological-status-in-a-real-world-population-of-glioblastoma-patients-treated-with-radiotherapy-and-temozolomide-a-single-center-prospective-study
#8
Giuseppe Lombardi, Eleonora Bergo, Paola Del Bianco, Luisa Bellu, Ardi Pambuku, Mario Caccese, Leonardo Trentin, Vittorina Zagonel
BACKGROUND: Health-related quality of life (HRQoL), cognitive function, and psychological status represent an important focus during the treatment of glioblastoma patients. Nevertheless, few randomized, prospective clinical trials have analyzed these factors, and very little is known in the real-clinical world. We evaluated these characteristics in glioblastoma patients treated with standard first-line therapy outside clinical trials. PATIENTS AND METHODS: In total, 111 newly, histologically diagnosed glioblastoma patients treated at our oncology center with radiotherapy and temozolomide were prospectively enrolled...
May 10, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29747854/-the-french-health-care-funding-system-for-research-and-innovation-in-oncology
#9
REVIEW
Harvey Wiernik, Gregory Katz, Hélène Coulonjou, André Salagnac, Frédéric Kletz, Juliette Thariat
INTRODUCTION: This article provides an overview of the French health system with respect to allocation of public resources to hospitals, to encourage research and innovation, particularly in the field of oncology. It is explained in a historical, economic and scientific perspective. RESULTS: Important structural and conceptual reforms (T2A, HPST law, etc.) have been carried out. These have significantly impacted the way public funding is allocated. Funding of innovation and research has been modified into a more incentive logic, aimed at strengthening competitiveness between all health care actors...
May 7, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29746187/queensland-youth-cancer-service-a-partnership-model-to-facilitate-access-to-quality-care-for-young-people-diagnosed-with-cancer
#10
Natalie K Bradford, Roslyn Henney, Rick Walker, Euan Walpole, Glen Kennedy, Wayne Nicholls, Ross Pinkerton
Global recognition of the need to improve outcomes for adolescents and young adults (AYA) with cancer has led to the development of specific oncology programs and services. In Australia, Youth Cancer Services (YCS) are now established across the country. While each service has been shaped by nationally agreed principles, program development has been influenced by local policy and geographic differences. Queensland is a vast state with a widely dispersed population; coordination of cancer services for young people across this landscape presents unique challenges...
May 10, 2018: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/29743988/molecular-mechanisms-underlying-curcumin-mediated-therapeutic-effects-in-type-2-diabetes-and-cancer
#11
REVIEW
Marzena Wojcik, Michal Krawczyk, Pawel Wojcik, Katarzyna Cypryk, Lucyna Alicja Wozniak
The growing prevalence of age-related diseases, especially type 2 diabetes mellitus (T2DM) and cancer, has become global health and economic problems. Due to multifactorial nature of both diseases, their pathophysiology is not completely understood so far. Compelling evidence indicates that increased oxidative stress, resulting from an imbalance between production of reactive oxygen species (ROS) and their clearance by antioxidant defense mechanisms, as well as the proinflammatory state contributes to the development and progression of the diseases...
2018: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29732928/influence-of-expedited-programs-in-the-united-states-on-oncology-drug-development-in-japan
#12
Makoto Tanaka, Naoki Matsumaru, Katsura Tsukamoto
BACKGROUND: Recent trends in globalization and the complexity of drug development have resulted in the possibility that expedited programs in one country may now influence drug development in another. We examined the effects of expedited programs in the United States on the development of oncology drugs in Japan. METHODS: Among oncology drugs approved in Japan between 2007 and 2016, we analyzed those that were approved in both the United States and Japan. The development period was calculated by subtracting the start date of the first clinical study or the investigational new drug application date from the drug approval date in the respective country...
January 1, 2018: Therapeutic Innovation & Regulatory Science
https://www.readbyqxmd.com/read/29730298/exploring-the-biophysical-properties-of-phytosterols-in-the-plasma-membrane-for-novel-cancer-prevention-strategies
#13
REVIEW
Omar Fakih, Didem Sanver, David Kane, James L Thorne
Cancer is a global problem with no sign that incidences are reducing. The great costs associated with curing cancer, through developing novel treatments and applying patented therapies, is an increasing burden to developed and developing nations alike. These financial and societal problems will be alleviated by research efforts into prevention, or treatments that utilise off-patent or repurposed agents. Phytosterols are natural components of the diet found in an array of seeds, nuts and vegetables and have been added to several consumer food products for the management of cardio-vascular disease through their ability to lower LDL-cholesterol levels...
May 3, 2018: Biochimie
https://www.readbyqxmd.com/read/29726374/does-global-oncology-need-artificial-intelligence
#14
Bishal Gyawali
No abstract text is available yet for this article.
May 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29723235/effects-of-anma-therapy-japanese-massage-on-health-related-quality-of-life-in-gynecologic-cancer-survivors-a-randomized-controlled-trial
#15
Nozomi Donoyama, Toyomi Satoh, Tetsutaro Hamano, Norio Ohkoshi, Mamiko Onuki
OBJECTIVES: Anma therapy (Japanese massage therapy, AMT) significantly reduces the severity of physical complaints in survivors of gynecologic cancer. However, whether this reduction of severity is accompanied by improvement in health-related quality of life is unknown. METHODS: Forty survivors of gynecologic cancer were randomly allocated to either an AMT group that received one 40-min AMT session per week for 8 weeks or a no-AMT group. We prospectively measured quality of life by using the Japanese version of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3...
2018: PloS One
https://www.readbyqxmd.com/read/29722363/pediatric-kaposi-sarcoma-in-context-of-the-hiv-epidemic-in-sub-saharan-africa-current-perspectives
#16
REVIEW
Nader Kim El-Mallawany, Casey L McAtee, Liane R Campbell, Peter N Kazembe
The global experience with pediatric Kaposi sarcoma (KS) has evolved immensely since the onset of HIV (human immunodeficiency virus). In this review, current perspectives on childhood KS are discussed in the context of the HIV epidemic in sub-Saharan Africa. Endemic (HIV-unrelated) KS was first described over 50 years ago in central and eastern Africa, regions where human herpesvirus-8, the causative agent of KS, is endemic. With the alarming rise in HIV prevalence over the past few decades, KS has become not only the most common HIV-related malignancy in Africa, but also one of the most common overall childhood cancers throughout the central, eastern, and southern regions of the continent...
2018: Pediatric Health, Medicine and Therapeutics
https://www.readbyqxmd.com/read/29721042/a-real-world-data-study-to-evaluate-treatment-patterns-clinical-characteristics-and-survival-outcomes-for-first-and-second-line-treatment-in-locally-advanced-and-metastatic-urothelial-cancer-patients-in-germany
#17
Günter Niegisch, Holger Gerullis, Shih-Wen Lin, Julie Pavlova, Adam Gondos, Anja Rudolph, Gabriele Haas, Nora Hennies, Mario W Kramer
Background : Worldwide, urothelial carcinoma (UC) is a common cause of morbidity and mortality. In particular, the incidence of bladder cancer varies widely across Europe; Germany has the ninth highest international age-standardized incidence. For advanced UC or metastatic UC (mUC), platinum-based combination chemotherapy is the standard first-line (1L) treatment; however, there is wide heterogeneity of second-line (2L) treatments, ranging from vinflunine in parts of Europe to taxanes and other agents elsewhere in Europe, in the United States and globally...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29720406/contemporary-prostate-biopsy-reporting-insights-from-a-survey-of-clinicians-use-of-pathology-data
#18
Murali Varma, Krishna Narahari, Malcolm Mason, Jon D Oxley, Daniel M Berney
AIM: To determine how clinicians use data in contemporary prostate biopsy reports. METHODS: A survey was circulated to members of the British Association of Urological Surgeons and the British Uro-oncology Group. RESULTS: Responses were received from 114 respondents (88 urologists, 26 oncologists). Ninety-seven (94%) use the number of positive cores from each side and 43 (42%) use the % number of positive cores. When determining the number and percentage of positive cores, 72 (71%) would not differentiate between targeted and non-targeted samples...
May 2, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29719974/global-medicinal-chemistry-and-gcpr-conference
#19
Laurent Schio
Laurent Schio speaks to Benjamin Walden, Commissioning Editor. Laurent Schio is leading the group of Integrated Drug Discovery of Sanofi, France. He joined Sanofi more than 25 years ago and is an organic chemist by training. He has made most of his career in medicinal chemistry supporting and leading projects, especially in the anti-infective and then in the oncology fields. He has developed a strong expertise in kinases and lately has contributed to the discovery of several clinical candidates for cancer treatment...
May 3, 2018: Future Medicinal Chemistry
https://www.readbyqxmd.com/read/29714573/a-pilot-experiment-in-responding-to-individual-patient-requests-for-compassionate-use-of-an-unapproved-drug-the-compassionate-use-advisory-committee-compac
#20
Arthur Caplan, Alison Bateman-House, Joanne Waldstreicher, Lisa Fedor, Ramana Sonty, Tito Roccia, Jon Ukropec, Rick Jansson
BACKGROUND: Janssen Research & Development, LLC, part of the Janssen pharmaceutical companies of Johnson & Johnson, and NYU School of Medicine partnered to establish the Compassionate Use Advisory Committee (CompAC) to evaluate the use of an independent, external, expert committee in ensuring transparent, fair, beneficent, evidence-based, and patient-focused compassionate access to investigational medicines, a public health challenge that has been an ongoing issue for over 3 decades...
January 1, 2018: Therapeutic Innovation & Regulatory Science
keyword
keyword
15240
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"